BPC-157 dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 250 mcg dose equals 10 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical BPC-157 dose is 0.25 mg. Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer daily (anecdotal protocols). Half-life of 4 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Anecdotal protocols run 4 to 6 weeks on, then off; no controlled human data to support specific cycling

   Open tool →
5. 5

   Monitor for side effects

   Watch for: injection-site irritation; nausea; headache (anecdotal). Stop or reduce dose if tolerability breaks down.

Why this dose

Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical.

The typical 0.25 mg dose is the figure most commonly used in published protocols for BPC-157. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

BPC-157 is administered via the subcutaneous, intramuscular, oral routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Half-life note: Short plasma half-life in preclinical models; IM/SC routes show sustained local tissue effects beyond plasma window

Cycling and tolerance

Anecdotal protocols run 4 to 6 weeks on, then off; no controlled human data to support specific cycling

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
• Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
• Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
• No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
• Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
• Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists

Side effects and interactions

Common side effects

• injection-site irritation
• nausea
• headache (anecdotal)

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full BPC-157 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not FDA approved; not scheduled; research-chemical status

Pregnancy

Insufficient data

Legal status

Not FDA approved; research-use-only grey market; banned by WADA (2022)

Do not use if

• pregnancy
• active malignancy (theoretical angiogenic concern)
• no established safety profile in humans

Related research